Objectives. The goal of this study was to assess the success of the morphine microdose method in a community pain clinic setting by monitoring followup frequency, dose escalation, and monotherapy/ polytherapy ratio. The morphine microdose method involves a pretrial reduction or elimination of systemic opioids followed by a period of abstinence. Intrathecal (IT) morphine is then started at doses of less than 0.2 mg per day. Systemic opioid abstinence is then continued after pump implant and IT morphine monotherapy.
Introduction
Intrathecal drug delivery systems (IDDS) have been used to manage chronic pain for more than 30 years. Initially, IDDS showed successful analgesia for cancer pain [1, 2] and was later extended for noncancer pain treatment. The assumption that intrathecal (IT) morphine would be as successful in treating noncancer pain as it was for cancer pain was flawed due to differences in pathology and dosing protocols. In noncancer pain, IDDS was initially approved for baclofen infusion for movement disorders. Although many case studies and case series provide positive evidence for the use of IDDS in noncancer pain, stronger evidence is lacking due to the paucity clinical trials [3] . For noncancer patients, analgesia is greatly enhanced at the start of therapy, but this effect does not last long. Eventually, IDDS contains mixtures of either high-dose morphine (>10 mg/d) or alternate non-US Food and Drug Administration-approved opioids, and/or nonopioid agents. The optimization of analgesia with IDDS can result in concurrent use of IT and systemic drugs, which can increase side effects due to polypharmacy, and/or addition of unapproved drugs to the pump mixture, which can cause pump corrosion and malfunction [4] .
The practice of IDDS is highly variable. According to surveys, 15% of physicians discontinued opioids and 40% significantly reduced opioids weeks before the trial, 22% discontinued systemic opioids during the IT trial, and 33% made no changes prior to trialing [5] . Some physicians chose starting doses of less than 1.0 mg/d (36% of responders) while others chose starting doses in the range of 1.0 to 2 mg/d (25% of responders) [6] . Dose escalation also appears to vary widely, with average maintenance doses reported to be 3.5 to 9.6 mg/d at year 1 and 7.42 to 12.2 mg/d at year 2.4 to 3 [7] [8] [9] [10] . The variability of pretrial systemic opioid adjustments, starting doses, and dose escalation demonstrates the diversity in IT pain practices.
Over the last decade, clinicians have tried to limit 24-hour opioid dose and dose escalation. Two studies have shown successful analgesia with IT doses much lower than traditionally used: a method referred to as "microdose." In 2011, Grider et al. described a method where patients discontinued all oral opioids and completed a six-week period without opioids prior to the IT trial. Then, IT therapy was initiated in a microgram dose range of morphine and titrated to achieve adequate analgesia in the hospital setting [11] . This was the first article to show efficacy of microdosing and that microdose therapy was an effective replacement for systemic therapy. In 2012, Hamza et al. described a method where patients decreased their oral medications by half before the IT trial. The placebo effect was tested during the trial, and three out of 61 patients reported greater analgesia with the placebo. After a positive inpatient trial, patients abstained from opioids seven to 10 days before implant. IT therapy was maintained in the low milligram range (<2 mg/d) of morphine. Throughout the study, patients were allowed to continue oral opioids, but they showed a decrease in use by the third month. Collectively, these studies have described the microdose method, which provides satisfactory pain relief with low IT doses, limited dose escalation, and successful reduction of oral opioids [11, 12] .
The definition of low-or microdose morphine has yet to be determined. There is no consensus on the microdose range or upper limit of doses. Furthermore, the relative contribution of factors (dose, concentration, infusion rate, and/or opioid abstinence) to the success of microdose therapy is also unknown. Further studies are needed to determine the impact these factors have on microdose success.
The microdose method is very attractive due to the low dose, which will decrease the occurrence of a catastrophic effect due to programming errors or bridge bolus errors. The microdose method should also reduce side effects; especially catheter tip granuloma formation. Morphine concentration was shown to be the primary contributor to IT granuloma formation at the catheter tip in a dog model, but this had not been confirmed in humans [13] . A recent systematic review showed significant correlation of two factors, dose and concentration, to granuloma formation [14] . Although catheter tip granuloma is rare, if not recognized and treated appropriately, irreversible neurological damage can ensue. Therefore, the most important advantage of the microdose method is safety.
This study is the first description of the microdose method in "real life" private and academic clinics. We have modified the microdose method from inpatient to outpatient trials to improve convenience and cost-effectiveness. Through retrospective chart review of six years of microdose practice, we examined morphine monotherapy success, dose escalation, and side effects.
Methods

Study Design
The study was a retrospective review of 60 chronic noncancer pain patients seen at the UTMB MultiSpecialty Center and Space City Pain Specialists that underwent a microdose IT opioid trial between June 11, 2008 , and October 11, 2014. We reviewed the electronic medical records to determine the patient characteristics pretrial, trial results, and efficacy of microdose therapy. We recorded the following pretrial information for each patient: age, date of birth, diagnosis, location of pain, average pain score before trial, pain medications, and side effects. The following trial information was collected: wean period, duration of opioid abstinence, trial date, IT dose, and side effects. Postimplant information, that is, implant date, age at implant, initial rate of infusion, side effects, pain score, rate change, and pain score for each follow-up visit, was collected.
Microdose Method
We have modified this technique from an inpatient to an outpatient trial. All of the patients complied with our office policy. This included a urine drug test on initial visit, followed by repeat tests every six to 12 months. We also reviewed the online prescription monitoring program Prescription Access in Texas to ensure that we are the only prescriber of opioids. Each patient signed a pain contract and agreed to not take other people's medication, not use pain medication prescriptions from other providers, and not take any type of medication without a prescription. Each patient understood that a violation would result in his or her dismissal from the Efficacy, Safety, and Feasibility of the Morphine Microdose Method clinic. The patients were weaned off systemic opioid medications and maintained in an opioid-free period for four to six weeks. Patients returned to the clinic for evaluation including a full history and physical exam, psychiatric evaluation, and counseling on the risks, benefits, and expectations of IDDS. After the evaluation was complete, both physician and patient agreed that IDDS might provide better pain relief compared with either the previous systemic medication regimen or the current medication-free state. The failure of systemic opioid therapy was defined as intolerable side effects and/or inadequate pain relief after multiple trials with different opioids. In addition, we added adjuvant medications, such as anti-inflammatory, antidepressant, and/or antiepileptic medications, when opioids and the combination failed to improve pain relief. In an ambulatory surgery center, the patient received a trial IT morphine injection. After positioning prone and sterile prep, a 25-gauge Whitacre needle was advanced through the introducer. Cerebrospinal fluid was confirmed, and Omnipaque 300 dye demonstrated intrathecal spread. Next, 1 mL of diluted Duramorph was injected into the intrathecal space, followed by 0.5 mL of saline. The patients received an injection of 12.5 to 125 mcg of IT morphine. As there were no guidelines or data on trial microdosing, we attempted various trial doses and eventually settled on 50 mcg/d. Most patients received the 50 mcg/d trial dose. The 12.5 mcg/d trial dose was chosen for patients who were completely intolerant of systemic opioid side effects. After a 30-to 40-minute observation period and having met postanesthesia discharge criteria, the patients were allowed to go home and were instructed to record average pain score over the next 24 hours and to not take any oral medication. An appropriate candidate had 50% pain reduction without side effects. Permanent implant occurred two to three weeks after a successful trial.
Statistical Methods
The IBM SSPS statistical program was used to analyze data, and Kaleidagraph version 4.1.3 was used to produce graphics. Patient demographic and pretrial opioid use and pain score between successful and unsuccessful morphine monotherapy groups were compared by t test for continuous variables and chi-square test or Fischer's exact test for categorical variables. A mixed model was used to examine the difference in means of opioid use and pain score across years. We also used a random slope model to analyze the rate of dose escalation. Statistical significance was represented by P values of less than 0.5. Means were reported as mean 6 standard error of the mean (SEM).
Results
Participants
After the approval by the Institutional Review Board at the University of Texas Medical Branch, a review of electronic medical records for all patients who completed a systemic opioid wean, opioid abstinence, and microdose morphine trial between the dates of June 11, 2008 , and September 24, 2014, was completed. Participants were included in the study if they were age 18 years or older, had a chronic noncancer pain diagnosis, and failed systemic opioid therapy. Patients were excluded if they had a preexisting diagnosis of cancer or other degenerative neuromuscular disease.
Pretrial Demographics
A total of 60 patients completed opioid wean, opioid abstinence, and a microdose trial. All patients were tested with a urine drug screen, and the results were consistent with their prescribed medications. We confirmed that we were the only provider of pain medication by online prescription monitoring program. During the opioid wean, each patient determined the rate that he or she would like to decrease systemic opioids. The opioid wean duration varied from immediate discontinuation of medication, that is, a "cold turkey" approach, to a gradual taper over three to four weeks. All patients, including those with the cold turkey approach, abstained from systemic opioids and benzodiazepines for a total four to six weeks. All patients had demonstrated compliance with our pain contract before being selected for a trial. We did not test patients after drug weaning to confirm drug abstinence but were confident in our signed pain contract agreement that they had completed their wean and period of abstinence. Most patients reported increased pain scores during weaning and the first week of abstinence. The pain intensity then subsided and was not worse than pretrial. The microdose trial consisted of a single IT injection under fluoroscopic guidance. The patients were observed in the postanesthesia care unit for 30 to 40 minutes, and after meeting postanesthesia discharge criteria-eating, drinking, and a return of baseline heart rate, blood pressure, and oxygen saturation-they were sent home. There were no complications such as respiratory depression that required hospitalization. After two to three weeks, pumps were implanted in successful trial patients. Patients received a starting dose from 12.5 to 125 mcg/d. In our first few patients, we used higher doses, such as 100 to 125 mcg/d, but found that 50 mcg/d was a good starting point for a majority of patients. If the patient was intolerant of systemic opioid side effects, we chose a lower starting dose of either 12.5 or 50 mcg/d. We did not use a conversion factor to calculate IT dose from the systemic dose.
The patient gender and diagnostic groups are summarized in Table 1 . There was a 7:3 ratio of females to males. The pain diagnoses were grouped as follows: cervical, lumbar, chronic pain syndrome (CPS), failed surgery syndrome (FSS), and other. The cervical group of diagnosis included cervical stenosis, cervical degenerative disc disease, cervical spondylosis, and cervical radiculopathy. The lumbar group of diagnoses included lumbar stenosis, lumbar degenerative disc disease, lumbar spondylosis, and lumbar radiculopathy. Chronic pain syndrome is defined as chronic pain associated with psychosocial dysfunction [15] . The failed back surgery syndrome group included patients with either previous cervical or lumbar surgeries and continued chronic pain. The other category included rheumatoid arthritis, vertebral compression syndrome, systemic lupus, fibromyalgia, and knee osteoarthritis. There was no significant difference in gender or primary diagnosis between those who were successful with morphine monotherapy and those who were unsuccessful.
Age, Pretrial Opioid Use, and Pain Scores
The average age at implant was 63.8 6 11.8 years. The morphine equivalent daily dose (MEDD) was determined by converting all opioids taken in 24 hours into morphine equivalents using the Texas Cancer Pain Initiative opioid conversion chart [16] . The mean MEDD before the opioid wean was 160.9 6 444.6 mg. The median was 70, and the interquartile range (IQR) was from 35 to 140 mg MEDD. Two patients were opioid naïve due to intolerable side effects of systemic opioids. There was no significant difference in the age, MEDD, or pain score between the successful and unsuccessful morphine monotherapy groups (Table 2 ).
In the private pain practice, the patients completed global pain scale worksheets during each office visit. The pain scores of all visits prior to the microdose trial were averaged. In the academic pain practice, the patients reported their lowest, highest, and average pain score at each office visit. The average pain score before the microdose trial was recorded (Table 2 ). There was no significant difference in pain scores between successful and unsuccessful morphine monotherapy groups.
Microdose Method Groups
Sixty patients started with morphine monotherapy microdosing, but at some point during the observational period, the patients had one of the following changes to their therapy: switched to hydromorphone therapy (12%), had additional medications added to morphine (22%), had a pump explant (3%), were excluded from the study due to diagnosis of cancer or a degenerative disease, or had no change and continued with morphine monotherapy (56%). The diagram in Figure 1 shows the distribution of patients who required changes 7.2 6 2 7(6-9) 7.9 6 1.6 8 (7-9)
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Mean age at time of pump implant was calculated. Morphine equivalent daily dose in the prior morphine microdose trial was calculated. Pain score was the mean pain score 6 SD before systemic opioid wean. There was no significant association between age, MEDD, or pain score and success of morphine monotherapy. IQR ¼ interquartile range; MEDD ¼ morphine equivalent daily dose.
to their IT therapy during the study. Morphine monotherapy was the focus of this study and will be detailed later. The polytherapy group (N ¼ 13, 22%) consisted of patients who were not satisfied with the pain relief and either multiple opioids were tried or nonopioids were added to IDDS. The hydromorphone group (N ¼ 7, 12%) consisted of a change from morphine to hydromorphone monotherapy due to either ineffective pain control or intolerable side effects of morphine. The surgical complication group (N ¼ 2, 3%) consisted of patients who had pumps explanted due to infection. Three patients were excluded due to the development of either metastatic cancer or Huntington's Chorea. The largest group was successful morphine microdose monotherapy patients (35/60 ¼ 58%).
Outpatient Microdose Safety and Feasibility
Morphine microdose monotherapy was easily titrated and managed in an outpatient setting. Our office policy allows patients to request sooner follow-up for evaluation for dose change. The dose was increased if due to inadequate pain control of pain condition and not to psychological stressors or other acute pain conditions. Outpatient follow-up of microdose patients was more frequent in the first month, followed by a gradual decrease in clinic visits over four months. During the first month, the patients had 2.1 visits per month. By the fifth month, the patients had a follow-up visit every other month. After five months, the patients had steady follow-up visits every two to three months for IT maintenance (data not shown). At no time did any patient experience a severe side effect such as respiratory depression, excessive sedation, or hypotension that required hospitalization.
Dose Escalation
Dose escalation is an important factor that determines the success of IT therapy. At the completion of the study, the patient's duration of therapy was from 54 days for the most recently implanted microdose patient to 1,634 days for the first microdose patient. Only the patients who had microdose therapy for longer than 150 days were included in this analysis. The lowest dose was 54 mcg/d, and the highest dose was 2,597 mcg/d. Figure 1 Microdose patient groups. Among the 60 patients who completed the microdose studies, 35 patients completed morphine monotherapy. Polytherapy is defined as morphine plus another drug and was completed by 13 patients. Hydromorphine monotherapy is hydromorphone only and was completed by seven patients. Surgical complications that required removal of the pump occurred in two patients. Three patients were excluded due to a diagnosis of cancer or degenerative neurological disease after the implant. 
Pain Scores
The pain score premicrodose trial was the average score on systemic opioids (year 0). The mean scores 6 SE were for years 1 (4.3 6 0.6, P < 0.0001), 2 (3.76 6 0.7, P < 0.0001), 3 (4.7 6 0.8, P ¼ 0.0011), and 4 (2.8 6 0.8, P ¼ 0.0001), and they were significantly lower than year 0 (7.5 6 1.9). Figure 3 shows the IQR of the average pain scores prior to starting microdose therapy (year 0) and for years 1, 2, 3, and 4 of microdose therapy. There was no significant difference between the years and no correlation with the increasing doses.
Rate of Dose Escalation
The time course of morphine doses was graphed for each patient. The y-intercept (starting dose) was tightly grouped compared with the ending doses. The random slope model was used to analyze the rate of dose escalation in the morphine microdose group using SPSS. This model allows the slope to vary and assumes that the intercept is constant. The slope (dose escalation) of the group was analyzed. The average slope 6 SD range included 19 patients. Figure 4 shows the dose escalation with the average slope (average). Seven patients had dose escalation significantly higher than average (higher). Nine patients had dose escalation significantly lower than average (lower). Figure 4 shows the dose escalation of the three groups. Most patients (19/35, 54.3%) had an average rate of dose escalation. The other patients were roughly split into lower (25.7%) and higher (20%) rates of dose escalation. The mean rates of dose escalation were 529.6 6 56.96 mcg/d/y in the higher group, 191.6 6 24.8 mcg/d/y in the average group, and 43 6 9.6 mcg/d/y in the lower group.
Discussion
This study describes the microdose method in both private and academic pain practices. We showed the successful weaning of systemic opioids and maintenance of opioid abstinence for four to six weeks in an outpatient setting. Microdose trials were safely done in an ambulatory surgery center, which was more convenient and cost-effective than inpatient trialing. No patients were hospitalized for respiratory depression, urinary retention, or excessive sedation. The majority of patients (35/60, 58%) who completed the outpatient microdose trial continued to be successfully managed solely on microdose morphine monotherapy. These patients did not require additional oral therapy and were satisfied with a pump programmed to allow patient-delivered boluses. We gave patients the ability to activate 10 to 20 mcg boluses three times a day. Many patients and their families reported personality changes, less depression, improved Efficacy, Safety, and Feasibility of the Morphine Microdose Method concentration, and decreased constipation. Due to the retrospective nature of this study, we were not able to quantify these improvements. There was a significant reduction in mean pain scores from 7.5 6 1.9 before microdose therapy to 4.3 6 .6 after one year of microdose therapy. All of the patients exhibited dose escalation. Roughly half of the patients had a dose escalation rate of 191.6 6 24.8 mcg/d per year.
The limitations of this study relate to the retrospective nature. Selection of patients who are able to wean and willing to commit to a microdose strategy can affect the outcome. We also chose to focus on the success of the morphine microdose method and, therefore, did not evaluate the success of other regimens such as hydromorphone or ziconitide. Furthermore, this study studied only those who had a successful trial and implant. Those who were not successful with the microdose IT trial were retrialed with either an increased dose or a morphine alternative, such as hydromorphone or ziconitide.
The microdose method, described by Grider, consisted of a complete cessation of systemic opioids followed by a period of abstinence [11] . The IT dose was initiated at 50 mcg/d and increased every 12 hours in an inpatient setting until adequate analgesia was achieved. The mean dose was 140 mcg/d at the end of the inpatient trial and 335 mcg/d after one year. The mean dose escalation can be estimated to be approximately (335-140 mcg/d/y) 195 mcg/d/y. In our studies, the mean starting dose (year 0) (Figure 2 ) was 68.46 9.7 mcg/d, and after one year it was 317 6 109.3 mcg/d. Our dose escalation was determined by plotting each patient's dose escalation data over four years and by analyzing this data with the random slope model. The dose escalation was divided into three significantly different groups: low, average, and high ( Figure 4 ). Our average dose escalation group (191 mcg/d/y) was similar to that of Grider's study, but we did have approximately half of our patients with either significantly lower or higher rates of dose escalation.
Hamza showed a successful microdose method using a higher range of doses (1.4 mg/d) [12] . In addition, this study differed from our study in that patients were incompletely weaned from systemic opioids and were strongly encouraged to participate in 12 weeks of physical therapy following implant. Follow-up visits were scheduled every six months for the first two years, and the last visit was at year 3. Patients were allowed to continue oral opioid therapy throughout the study, but the use of oral opioids decreased from 126.7 to 3.8 mg MEDD after three months of IT therapy [12] . The mean maintenance oral dose at year 3 was 1.68 6 0.3 mg/d. The mean IT doses at six and 36 months were 1.4 and 1.58 mg/d. The mean dose escalation, estimated by calculating the difference between the initial and final mean doses and then dividing by time, was 56 mcg/d/y. In our study, we recorded every dose change in the study period, resulting in many more points to define dose escalation. The random slope model analyzed each patient's morphine time course graph to determine the dose escalation and determined the average dose escalation 6 SD of the group. The patients with dose escalation below the average range were in the low dose escalation group. In our study, only the low dose escalation group (43 mcg/d/y), showed a dose escalation similar to Hamza's study. A majority of our patients had dose escalation rates that fell within the average (N ¼ 19) , and the high (N ¼ 7) dose escalation group had significantly higher rates (91.6 6 24.8 and 529.6 6 56.96 mcg/d/y, respectively). The high dose escalation group was comprised of patients with dose escalation that was higher than the average. This could be due to major differences between these studies such as the lack of oral medication, lack of exercise program, and/or increased number of appointments available to patients.
Our patient population differed from those in the Grider and Hamza studies in that there was more heterogeneity of dose escalation in our population. Several factors explain the heterogeneity of dose escalation in our patients. Our patients had increased access to the pain clinic and could request sooner follow-up appointments and dose increases as opposed to the set schedule of a clinical trial. Our patients also had multiple available treatment options if analgesia was not satisfactory. Drugs such as bupivacaine, clonidine, or ziconitide were added to or replaced morphine. This polytherapy group represented 22% of our patients. Our patients were also given the option to switch to hydromorphone either due to intolerable side effects or unsatisfactory analgesia. The hydromorphine group represented 12% of our patients. The heterogeneity of our population highlights the differences between clinical studies and real-life practices. The breakdown of our patient population (outlined in Figure 1) shows that the microdose method with morphine monotherapy was successful for a majority of patients (58%).
The definition of the microdose method has generated much debate. What is the upper limit of the microdose? This is currently unknown. We suggest that the upper limit is the dose at risk for catheter tip granuloma formation. compared their patients receiving morphine IT therapy without granuloma formation to a systemic review of granuloma case reports to determine factors promoting granuloma formation [14] . They found that both dose and concentration of morphine were major factors in granuloma formation. The median dose in the granuloma-free group (-G) was 2.8 mg/d, and in the granuloma group (þG) it was 15 mg/d. In our study, the doses remained well below the þG group. Theoretically, even our patients in the higher dose escalation group would require approximately 29 years to reach the dose of the þG group. They also showed that the mean concentrations of morphine in the þG group were 20 mg/mL. The concentration of morphine used for our patients was 2 mg/mL, which is well below the concentration in the þG group. The mean time span for granuloma formation reported by was 39.5 6 13.5 months [10] . Our patients had a duration of therapy of up to 1,634 days (54.5 months ¼ 4.5 years) without incidence of granuloma formation.
Initially IDDS implantation costs more than systemic opioid management, but this cost is offset by the second year [17] . The outpatient microdose trialing method significantly reduces the first-year costs of IDDS. For example, in our area, the cost for a Medicare patient with one to two comorbidities for outpatient trial is $855 compared with $5,600 for an inpatient trial. Furthermore, discontinuing systemic opioids after IDDS implantation has been shown to reduce cost by 10% to 12% in annual inpatient, outpatient, and drug expenditures [18] . Therefore, the outpatient microdose method reduces cost by both reducing trial costs and eliminating systemic opioid use.
The microdose method achieves successful analgesia for 58% of patients trialed. The 10-fold lower concentration practically eliminates the risk of granuloma formation. The microdose method improves safety by decreasing the life-threatening consequences of programming errors and dosing errors. Furthermore, the microdose method is feasible, safe, and cost-effective in the outpatient setting. Further studies are needed to determine the mechanism(s) and patient factors responsible for the success of microdose morphine monotherapy.
